Emcure Pharmaceuticals Limited (EMCURE) Stock Statistics & Valuation Metrics

Emcure Pharmaceuticals Limited has a market cap or net worth of ₹271.97B. The enterprise value is ₹210.27B.

Emcure Pharmaceuticals Limited has 189,572,540 shares outstanding. The number of shares has decreased by -2.65% in one year.

Emcure Pharmaceuticals Limited’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 17.61%.

The current PE Ratio of Emcure Pharmaceuticals Limited is 31.2. Emcure Pharmaceuticals Limited’s PEG ratio is 0.00.

In the last 12 months, Emcure Pharmaceuticals Limited had revenue of 78.08B and earned 6.81B in profits. Earnings per share was 0.43.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

Emcure Pharmaceuticals Limited pays an annual dividend of ₹3, resulting in a dividend yield of 0.21%

Emcure Pharmaceuticals Limited upcoming earnings date is May 21, 2026, During Market Hours (Confirmed).

Emcure Pharmaceuticals Limited as a current ratio of 1.71, with Debt / Equity ratio of ―

In the past 12 months, Emcure Pharmaceuticals Limited has paid 30.85M in taxes.

Emcure Pharmaceuticals Limited EV to EBITDA ratio is 14.06, with an EV/FCF ratio of 47.28.

Emcure Pharmaceuticals Limited has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of 13.89%, and net profit margin of 8.73%.

The average price target for Emcure Pharmaceuticals Limited is ₹1,780.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy